사카로마이세스 (여행자 설사)
Saccharomyces boulardii (Traveler)
📚 관련 논문 (23편)
1. Travel Med Infect Dis. 2024 May-Jun;59:102703. doi: 10.1016/j.tmaid.2024.102703. Epub 2024 Mar 7. Investigating the influence of probiotics in preventing Traveler's diarrhea: Meta-analysis based systematic review. Alharbi BF(1), Alateek AA(2). Author information: (1)Department of Basic Healt
2. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD003048. doi: 10.1002/14651858.CD003048.pub4. Probiotics for treating acute infectious diarrhoea. Collinson S(1), Deans A(2), Padua-Zamora A(3), Gregorio GV(3), Li C(4), Dans LF(3), Allen SJ(1). Author information: (1)Department of Clinical Scie
3. Travel Med Infect Dis. 2019 Jan-Feb;27:11-19. doi: 10.1016/j.tmaid.2018.09.007. Epub 2018 Sep 29. Are probiotics and prebiotics effective in the prevention of travellers' diarrhea: A systematic review and meta-analysis. McFarland LV(1), Goh S(2). Author information: (1)Department of Medicina
4. World J Gastroenterol. 2010 May 14;16(18):2202-22. doi: 10.3748/wjg.v16.i18.2202. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. McFarland LV. This article reviews the evidence for efficacy and safety of Saccharomyces boulardii (S. boulardii) for various d
5. Travel Med Infect Dis. 2007 Mar;5(2):97-105. doi: 10.1016/j.tmaid.2005.10.003. Epub 2005 Dec 5. Meta-analysis of probiotics for the prevention of traveler's diarrhea. McFarland LV(1). Author information: (1)Department of Health Services Research and Development, VA Puget Sound Health Care Sy
6. Lancet Infect Dis. 2006 Jun;6(6):374-82. doi: 10.1016/S1473-3099(06)70495-9. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Sazawal S(1), Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Author information: (1)Departm
7. PLoS One. 2018 Dec 26;13(12):e0209205. doi: 10.1371/journal.pone.0209205. eCollection 2018. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. Sniffen JC(1), McFarland LV(2), Evans CT(3)(4), Goldstein EJC(5). Author information: (1)Department of In
8. Travel Med Infect Dis. 2015 Mar-Apr;13(2):128-34. doi: 10.1016/j.tmaid.2015.03.001. Epub 2015 Mar 10. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Xie C(1), Li J(1), Wang K(2), Li Q(1), Chen D(3). Author information: (1)Department o
1. Infect Drug Resist. 2026 Apr 7;19:594118. doi: 10.2147/IDR.S594118. eCollection 2026. Vonoprazan-Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection. Qu DN(#)(1), Ji ZX(#)(1), Zhang JQ(2), Wang XY(1). Author information: (1)Department of Gastroenterology, the Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, People's Republic of China. (2)Department of Pathology, the Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, People's Republic of China. (#)Contributed equally BACKGROUND: Whether the incorporation of Saccharomyces boulardii (S. boulardii) into vonoprazan-amoxicillin dual therapy contributes to improved eradication rate and a lower frequency of adverse events in rescue regimens for Helicobacter pylori (H. pylori) infection has yet to be established. METHODS: In a single-center, randomized controlled trial, 190 adults with previous H. pylori treatment failure were assigned to receive either vonoprazan (20 mg twice daily) plus amoxicillin (750 mg three times daily) (VA group) or the same regimen with S. boulardii (250 mg twice daily) (VAS group) for 14 days. Eradication rates, compliance, adverse events, and safety were assessed. Risk factors influencing the eradication rate were explored. RESULTS: Based on intention-to-treat analysis, H. pylori eradication rates were 80.0% in the VA group and 92.6% in the VAS group (P = 0.011), and per-protocol analysis yielded eradication rates of 85.4% and 94.6%, respectively (P = 0.037). There were no significant differences in eradication rates for either the VA regimen (P = 0.736) or the VAS regimen (P = 0.431) based on the number of previous treatment failures. However, a history of prior furazolidone use reduced the eradication rate of VAS therapy. The incidence of adverse events was significantly lower in the VAS group (11.6%) than it was in the VA group (32.6%; P < 0.001). Both groups showed similar good compliance and safety. CONCLUSION: Supplementing vonoprazan-amoxicillin dual therapy with S. boulardii significantly increases H. pylori eradication rates and reduces adverse events, offering an effective and simple rescue treatment unaffected by previous treatment failures. TRIAL REGISTRATION: Chinese Clinical Trial Registry No. ChiCTR2300075382, September 4, 2023. © 2026 Qu et al. DOI: 10.2147/IDR.S594118 PMCID: PMC13069978 PMID: 41971394 Conflict of interest statement: The authors declared that they have no conflicts of interest regarding this work.
2. J Coll Physicians Surg Pak. 2025 Nov;35(11):1440-1446. doi: 10.29271/jcpsp.2025.11.1440. Efficacy and Safety of <em>Saccharomyces Boulardii</em> with Standard Quadruple Therapy for Eradication of <em>Helicobacter Pylori </em>in Adults: Meta-Analysis. Ma F(1)(2), Huang H, Tian K, Wang W(1)(2). Author information: (1)Department of Gastroenterology, Binzhou Medical University Hospital, Binzhou, China. (2)Department of General Practice Medicine, Binzhou Medical University Hospital, Binzhou, China. Helicobacter pylori is a class I carcinogen, strongly associated with gastric cancer, gastric ulcers, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Helicobacter pylori (H. pylori) infection necessitates effective eradication strategies. This study evaluated Saccharomyces boulardii (S. boulardii) as an adjunctive therapy to standard bismuth-containing quadruple therapy for H. pylori eradication. Comprehensive searches across PubMed, Embase, Cochrane Library, CNKI, WanFang Data, CBM, and Web of Science identified relevant randomised controlled trials (RCTs). Analysis of 11 RCTs (n = 2,295 patients) demonstrated significantly higher eradication rates (78.6% to 89.2%) with adjunctive S. boulardii (n = 2,295; ITT analysis: RR = 1.12; 95% CI: 1.06-1.18; Z = 4.27, p <0.01) versus standard therapy alone. Crucially, the probiotic combination also substantially reduced treatment-related adverse events (n = 2,183; RR = 0.46; 95% CI: 0.28-0.74; Z = 3.16; p = 0.002), with pronounced reductions in diarrhoea (n = 2,091; RR = 0.46; 95% CI: 0.22-0.93; Z = 2.15; p = 0.03) and rash occurrence (n = 1,271; RR = 0.33; 95% CI: 0.14-0.77; Z = 2.55; p = 0.01). These findings support S. boulardii supplementation as an effective strategy that enhances standard bismuth quadruple therapy efficacy while mitigating gastrointestinal and dermatological complications in H. pylori management. Therefore, the combination of S. boulardii and bismuth-containing quadruple therapy was effective in the treatment of H. pylori infection and has shown significant efficacy and safety as an effective and safe treatment. Key Words: Saccharomyces boulardii, Helicobacter pylori, Bismuth, Quadruple therapy. DOI: 10.29271/jcpsp.2025.11.1440 PMID: 41247686 [Indexed for MEDLINE]
3. Trials. 2025 Nov 10;26(1):484. doi: 10.1186/s13063-025-09230-w. Probiotics to reduce ventilator-associated pneumonia in adults with acute non‑anoxic brain injury: Study Protocol for a Double-Blind Multicenter Randomized International Clinical Trial (PROACT). Corriero A(1)(2), Soloperto R(3)(4), Giglio M(5), Salvagno M(4), Trerotoli P(6), Grasso S(3), Ribezzi M(3), Mosca A(7), Petrillo C(8), De Toma N(8), Magnesa G(9), Giacomucci A(10), Accattoli R(10)(11), Gadaleta RM(12), Florio M(12), Cariello M(12), Moschetta A(12), Puntillo F(13), Taccone FS(4), Ranieri VM(3). Author information: (1)Department of Interdisciplinary Medicine - ICU Section, University of Bari Aldo Moro, Piazza G. Cesare 11, Bari, 70124, Italy. alberto.corriero@gmail.com. (2)Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Route de Lennik 808, Brussels, 1070, Belgium. alberto.corriero@gmail.com. (3)Department of Precision and Regenerative Medicine and Jonian Area - ICU Section, University of Bari Aldo Moro, Bari, Italy. (4)Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Route de Lennik 808, Brussels, 1070, Belgium. (5)Department of Interdisciplinary Medicine - ICU Section, University of Bari Aldo Moro, Piazza G. Cesare 11, Bari, 70124, Italy. mariateresa.giglio@uniba.it. (6)Department of Interdisciplinary Medicine - Medical Statistics Section, University of Bari Aldo Moro, Piazza G. Cesare 11, Bari, 70124, Italy. (7)Department of Interdisciplinary Medicine - Microbiology Section, University of Bari Aldo Moro, Piazza G. Cesare 11, Bari, 70124, Italy. (8)UOC Anesthesia and Intensive Care, Ospedale "Di Venere", ASL Bari, Via Ospedale Di Venere 1, Bari, 70131, Italy. (9)ICU Section, Ospedale Miulli, Acquaviva Delle Fonti, Bari, Italy. (10)Intensive Care Unit, Azienda Ospedaliera Di Perugia, Piazzale G. Menghini 6/8, Perugia, 06156, Italy. (11)Department Di Medicine and Surgery, Anaesthetics, Analgesia and Intensive Care Section, University of Perugia, P.Le Lucio Severi, 1, Perugia, 06132, Italy. (12)Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Piazza G. Cesare 11, Bari, 70124, Italy. (13)Department of Interdisciplinary Medicine - ICU Section, University of Bari Aldo Moro, Piazza G. Cesare 11, Bari, 70124, Italy. filomena.puntillo@uniba.it. BACKGROUND: Ventilator-associated pneumonia (VAP) remains a significant complication among critically ill patients, with associated mortality approaching 50%. Despite the implementation of established preventive strategies, additional interventions are urgently needed to further reduce the incidence of VAP. Probiotic therapy has emerged as a promising adjunctive approach; the benefits of probiotic therapy may be more pronounced in critically ill patients without pre-existing infections. The PROACT study will evaluate the prophylactic role of probiotics in a critically ill population with acute brain injury to reduce the VAP incidence, while also exploring microbiological endpoints and mortality to refine patient selection criteria. METHODS: The PROACT study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of probiotic prophylaxis in adult critically ill patients requiring invasive mechanical ventilation following acute brain injury (e.g., head trauma, ischemic or hemorrhagic stroke). Patients with suspected pulmonary aspiration or pre-existing pulmonary infections at enrollment are excluded to reduce confounding. Participants are randomized in a 1:1 ratio to receive either a placebo (glucose polymer) or a probiotic formulation containing Lactobacillus acidophilus LA-5, Lactobacillus plantarum, Bifidobacterium lactis BB12, and Saccharomyces boulardii. The assigned intervention is administered twice daily via nasogastric tube and oropharyngeal application for up to 30 days or until intensive care unit (ICU) discharge. The primary endpoint is the incidence of VAP, as defined by current international guidelines, in the intention-to-treat (ITT) population. Secondary endpoints include the incidence of VAP in the modified intention-to-treat (mITT) population, catheter-related bloodstream infections, occurrence of sepsis and septic shock, 30-day all-cause mortality, ICU length of stay, and duration of mechanical ventilation. The study is powered at 80% (α = 0.05) to detect a clinically meaningful difference based on effect size estimates based on the PROVAP study, requiring a total sample size of 208 patients. All participating centers implement standard VAP prevention bundles as part of routine care. DISCUSSION: By evaluating the efficacy of probiotic therapy in preventing VAP and the impact on mortality among critically ill brain-injured patients, this trial has the potential to generate high-quality evidence supporting the incorporation of probiotics into standard VAP prevention protocols. The findings may have significant implications for clinical practice guidelines and public health policy related to infection control and microbiome-targeted interventions in the intensive care setting. TRIAL REGISTRATION: Registered at ClinicalTrials.gov (identifier: [NCT06092554]). Registered on 2023-10-15. © 2025. The Author(s). DOI: 10.1186/s13063-025-09230-w PMCID: PMC12599058 PMID: 41214813 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate {24}: The PROACT Trial protocol and informed consent forms will be approved by each hospital’s Research Ethics Board. Researchers will carry out this study in line with the GCP and the Declaration of Helsinki. Before randomization, patients or their legal representatives shall provide written informed consent. Consenting individuals will be made aware that if they choose to decline enrollment or withdraw from the study, it will not impact their care. Coded identification, password-protected documents and webpages, lockable filing cabinets, and offices will all be used to guarantee confidentiality. Consent for publication {32}: No identifiable personal data or images of participants will be published. As part of the informed consent process, participants or their legally authorized representatives will provide consent for the use of anonymized study data in scientific publications and presentations. Competing interests {28}: The authors declare that UNI‑PHARMA S.A. provided the investigational product and placebo in‑kind for this trial. Study design, data collection, analyses, interpretation, and manuscript preparation are the responsibility of the academic investigators. Relevant relationships with UNI‑PHARMA have been disclosed and managed per institutional policies.
4. Ter Arkh. 2025 Aug 28;97(8):660-667. doi: 10.26442/00403660.2025.08.203301. [Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors]. [Article in Russian; Abstract available in Russian from the publisher] Maev IV(1), Andreev DN(1), Shaburov RI(1)(2), Zaborovsky AV(1), Fomenko AK(1), Sokolov PS(1), Tsaregorodtsev SV(1), Devkota MK(1), Dicheva DT(1), Cheremushkin SV(1)(2), Cheremushkinа NV(1), Vychkin AV(1). Author information: (1)Russian University of Medicine. (2)Semashko RZD-Medicine Clinical Hospital. AIM: To evaluate the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use. MATERIALS AND METHODS: A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy (> 3 months) with confirmed SIBO. SIBO was diagnosed in all patients using a lactulose Hydrogen/Methane Breath Test (HMBT). Symptom severity was assessed using the validated "7 × 7" Questionnaire, and Quality of Life (QoL) was evaluated using the SF-36 Health Status Survey. Enrolled patients were randomized into two groups based on a 7-day treatment regimen: Group 1 received rifaximin (400 mg twice daily); Group 2 received rifaximin (400 mg twice daily) plus the probiotic Saccharomyces boulardii CNCM I-745 (Enterol® drug product, Biocodex, France; 500 mg twice daily). SIBO eradication was confirmed via repeat lactulose HMBT, and symptom severity/QoL were reassessed 4 weeks after treatment completion. RESULTS: 108 patients were enrolled (mean age 38.7 ± 8.9 years; 65.7% female). Mean PPI treatment duration at enrollment was 4.81 months (95% confidence interval 4.15-5.46). At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038). Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033). The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010). Both groups showed significant trends toward QoL improvement on the SF-36 survey. CONCLUSION: This prospective comparative study demonstrates that combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 appears more effective than rifaximin monotherapy for SIBO eradication, symptom regression, and QoL improvement in patients with PPI-associated SIBO. Publisher: Цель. Изучение эффективности комбинированной терапии с применением рифаксимина и Saccharomyces boulardii CNCM I-745 у пациентов с синдромом избыточного бактериального роста (СИБР) на фоне длительного приема ингибиторов протонной помпы (ИПП) в сравнении с монотерапией рифаксимином. Материалы и методы. Проведено проспективное сравнительное исследование в двух параллельных группах. Включению подлежали пациенты, длительно и непрерывно (более 3 мес) принимающие ИПП с верифицированным СИБР. Для верификации СИБР всем пациентам проводили водородно-метановый дыхательный (ДВТ) тест с лактулозой. Для объективизации выраженности клинической симптоматики проводилась оценка с использованием валидированного опросника «7 × 7», а для оценки динамики качества жизни (КЖ) применяли опросник КЖ SF-36 Health Status Survey. Пациенты, включенные в исследование, были рандомизированы на 2 группы в зависимости от получаемой в течение последующих 7 дней терапии: 1-я группа – рифаксимин (400 мг 2 раза в сутки); 2-я группа – рифаксимин 400 мг 2 раза в сутки и пробиотик Saccharomyces boulardii CNCM I-745 (лекарственный препарат Энтерол®, Biocodex, Франция), 500 мг 2 раза в сутки. Верификация эрадикации СИБР по данным ДВТ с лактулозой, а также повторная клиническая оценка выраженности симптоматики и КЖ пациентов проводились через 4 нед после завершения терапии. Результаты. В исследование были включены 108 пациентов (средний возраст 38,7 ± 8,9 года, 65,7% – женщины). Средняя длительность приема ИПП на момент включения в исследование составила 4,81 мес (95% доверительный интервал 4,15–5,46). Через 4 нед после лечения повторный ДВТ с лактулозой продемонстрировал, что в 1-й группе частота регистрации СИБР составила 41,5% (n = 22/53), тогда как во 2-й группе этот показатель был равен 21,8% (n = 12/55; p = 0,038). Полное статистически значимое купирование диареи отмечено только во 2-й группе (p = 0,033). Итоговый медианный балл по опроснику «7 × 7» после терапии оказался достоверно ниже во 2-й группе (p = 0,0010). В обеих группах отмечена значимая тенденция к улучшению КЖ по данным опросника SF-36. Заключение. Настоящее проспективное сравнительное исследование продемонстрировало, что комбинированная терапия с применением рифаксимина и Saccharomyces boulardii CNCM I-745 у пациентов с СИБР на фоне длительного приема ИПП в сравнении с монотерапией рифаксимином оказывается эффективнее в рамках эрадикации СИБР, регресса клинических проявлений и улучшения КЖ пациентов. DOI: 10.26442/00403660.2025.08.203301 PMID: 40884341 [Indexed for MEDLINE]
5. Int J Antimicrob Agents. 2025 Dec;66(6):107600. doi: 10.1016/j.ijantimicag.2025.107600. Epub 2025 Aug 25. The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: A systematic review and meta-analysis. Liu YH(1), Zhang J(2), Li DH(1), Zhang YP(1), Li J(3), Guo QQ(3), Zhu XJ(1), Shi YQ(4). Author information: (1)State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. (2)State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China; Department of Gastroenterology, Pingdingshan Medical District, Pingdingshan, Henan, China. (3)Postgraduate Department, Xi'an Medical University, Xi'an, Shaanxi, China. (4)State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Electronic address: shiyquan@fmmu.edu.com. BACKGROUND: Bismuth quadruple therapy (BQT) remains a cornerstone of first-line Helicobacter pylori eradication. However, its efficacy is increasingly undermined by antibiotic resistance, while frequent adverse events reduce its tolerability. Probiotics have been proposed as adjunctive agents to improve eradication outcomes and mitigate side effects, though their specific role in combination with BQT has yet to be fully established. METHODS: We conducted an extensive search of PubMed, Embase, Web of Science, and Cochrane Library for randomized controlled trials (RCTs) published through November 2024. Eligible studies compared H. pylori eradication rates and adverse events between probiotic-supplemented BQT (PBQT) and standard BQT in infected patients. RESULTS: Nineteen randomized controlled trials with 2973 samples were included. PBQT significantly improved H. pylori eradication rates compared to BQT alone (pooled odds ratio [OR] = 1.49, 95% confidence interval [CI] 1.20-1.85; P = 0.0004), with low heterogeneity (I² = 0%). Subgroup analyses demonstrated that both Saccharomyces boulardii (OR = 1.62; P < 0.05) and multi-strain probiotics (OR = 1.66; P < 0.05) significantly enhanced eradication rates. Concomitant administration of probiotics with antibiotics also yielded significant benefits (OR = 1.48, 95% CI 1.14-1.92; P = 0.003). PBQT demonstrated superior efficacy in the initial-treatment subgroup (OR = 1.48; P = 0.003) and among patients aged ≥18 y (OR = 1.47; P = 0.005). Regional subgroup analysis revealed a significant improvement in eradication rates for studies conducted in East Asia (OR = 1.66; P = 0.003). Antibiotic-specific subgroup analysis indicated a significant benefit of probiotics in the amoxicillin-clarithromycin BQT subgroup (OR = 1.59; P = 0.01). Overall, adverse events were significantly lower in the PBQT group (OR = 0.44, 95% CI 0.27-0.70, P = 0.0006), especially diarrhoea (OR = 0.33, 95% CI 0.21-0.52, P < 0.00001) and nausea (OR = 0.29, 95% CI 0.11-0.79, P = 0.02). CONCLUSIONS: Adding probiotics, particularly S. boulardii or multi-strain combinations, to BQT significantly improves eradication efficacy and decreases treatment-related adverse events. PBQT represents a pragmatic optimization of current first-line regimens and supports its incorporation into clinical practice to improve H. pylori treatment outcomes. Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.ijantimicag.2025.107600 PMID: 40865583 [Indexed for MEDLINE]
6. Front Cell Infect Microbiol. 2025 Jun 4;15:1587792. doi: 10.3389/fcimb.2025.1587792. eCollection 2025. Efficacy and safety of Saccharomyces boulardii CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis. McFarland LV(#)(1)(2), Li T(#)(3). Author information: (1)McFarland Consulting, Seattle, WA, United States. (2)Public Health Reserves Corps, Seattle, WA, United States. (3)Department of Gastroenterology, First Affiliated Hospital of Dalian Medical University, Dalian, China. (#)Contributed equally BACKGROUND: Pediatric acute gastroenteritis (PAGE) is a common cause of morbidity and mortality, especially in children under five years old. Therapeutic strategies including probiotics have been investigated, but trials from non-English speaking countries may not be easily accessible. AIM: To determine the efficacy of Saccharomyces boulardii compared to controls for treating PAGE in children receiving standard rehydration therapy in trials conducted in China. METHODS: Systematic review and meta-analysis using literature search with Google Scholar, PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure and China Biology Medicine disc (from inception to June 30, 2024) of randomized, controlled trials comparing S. boulardii CNCM I-745 to controls for the treatment of PAGE in children conducted in China. Independent data extraction by two reviewers. Standard meta-analysis methods were applied and random-effect or fixed-effects models were used depending upon the degree of heterogeneity using standardized mean differences for continuous data and relative risk estimates for dichotomous outcomes. The risk of bias for each study was determined and heterogeneity was measured by I2. RESULTS: Of 851 articles screened, 10 RCTs (1125 participants) met the inclusion criteria, and none were found in non-Chinese databases. S. boulardii CNCM I-745 was found to significantly reduce the duration of PAGE (SMD=-1.63 days, 95% CI -2.08, -1.18), improve the total effectiveness rating (RR=1.22, 95% CI 1.16, 1.28) and significantly more participants were cured (RR=1.47, 95% CI 1.30, 1.67). The finding that S. boulardii significantly reduced the levels of two pro-inflammatory cytokines (TNF-α and IL8) has not been reported in previous meta-analyses of PAGE. CONCLUSION: S. boulardii CNCM I-745 is an effective treatment for PAGE and was well tolerated in trials done in China. SYSTEMATIC REVIEW REGISTRATION: www.crd.york.ac.uk/PRSPERO, identifier CRD 42024567537. Copyright © 2025 McFarland and Li. DOI: 10.3389/fcimb.2025.1587792 PMCID: PMC12174131 PMID: 40535538 [Indexed for MEDLINE] Conflict of interest statement: Author LM was employed by McFarland Consulting and Public Health Reserve Corps. LM is a consultant for Biocodex France and Axon Pharma SAS South America and Dr. Reddy’s Laboratory India and is on the Microbiome Advisory Board Biocodex, France. The remaining author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
7. Support Care Cancer. 2025 Jun 17;33(7):590. doi: 10.1007/s00520-025-09663-8. Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoing pelvic radiotherapy for gynecologic cancers: a randomized controlled trial. Muangwong P(1), Tharavichitkul E(1), Thiennimitr P(2), Chitapanarux I(1), Kittidachanan K(1), Chitapanarux T(3). Author information: (1)Division of Radiation Oncology, Department of Radiation, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. (2)Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. (3)Gastrohepatology Unit, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. taned.chi@cmu.ac.th. PURPOSE: Acute gastrointestinal (GI) toxicities are common side effects of pelvic radiotherapy in gynecologic cancers. Although bacterial probiotics show promise, there is limited evidence for yeast-based probiotics such as Saccharomyces boulardii. This study aimed to evaluate the efficacy of S. boulardii in preventing acute radiation-induced GI toxicities in patients undergoing pelvic radiotherapy for cervical and endometrial cancers. METHODS: A prospective, randomized, double-blind, controlled trial was conducted with 60 patients receiving definitive or postoperative pelvic radiotherapy. Patients were randomized to receive either S. boulardii (250 mg/day) or a placebo, starting one week before radiotherapy and continuing throughout treatment. Acute GI toxicities were assessed weekly using the Common Terminology Criteria for Adverse Events (CTCAE) version 5. Stool consistency and inflammatory markers were also monitored. The primary outcome was the reduction in the severity of diarrhea and other GI symptoms. RESULTS: S. boulardii significantly reduced the incidence of type 6 and 7 stool consistency at week 3 (p = 0.01). However, despite this transient improvement, the treatment group experienced a significantly higher incidence of diarrhea at week 4 compared to the control group (p = 0.03). Overall, no significant differences were found between the groups in terms of cumulative GI toxicities or anti-diarrheal medication use, with diarrhea remaining the most common acute GI toxicity in both groups. CONCLUSION: No consistent effect of S. boulardii was observed across the measured outcomes, and its overall efficacy in preventing acute radiation-induced enteritis remains inconclusive. Further studies with larger sample sizes are warranted. TRIAL REGISTRATION: The study was registered with the Thai Clinical Trials Registry (TCTR20210204013) on 04 February 2021. © 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. DOI: 10.1007/s00520-025-09663-8 PMID: 40526282 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval: This study was approved by Research Ethics Committee No. 4, Faculty of Medicine, Chiang Mai University (No. 256/2564). The study was carried out in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Consent for publication: Not Applicable. Competing interests: The authors declare the following potential conflicts of interest: E.T. has received payment for presentations from Elekta and MSD. All other authors report no conflicts of interest.
8. Sci Rep. 2025 Jun 2;15(1):19326. doi: 10.1038/s41598-025-04986-2. Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial. Chitapanarux T(1), Wiracha U(2), Winichakoon P(3), Salee P(3), Traisathit P(4). Author information: (1)Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 50200, Chiang Mai, Thailand. thaitaned@yahoo.com. (2)Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 50200, Chiang Mai, Thailand. (3)Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. (4)Department of Statistics, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand. Clostridioides difficile infection (CDI) is a significant cause of hospital-acquired diarrhea, leading to high morbidity, recurrence, and healthcare costs. Probiotics like Saccharomyces boulardii show potential as an adjunct therapy to standard CDI treatment, but further trials are needed to confirm their efficacy. This study assessed the efficacy and safety of S. boulardii combined with vancomycin for treating mild to moderate CDI. 120 CDI patients diagnosed with positive stool toxin test were randomly assigned to receive two capsules of 250 mg of S. boulardii or a placebo every 12 h alongside 125 mg of vancomycin every 6 h for 10 days. The primary endpoint was the clinical cure rate, with secondary endpoints including recurrence, global cure rate, and diarrheal outcomes. Clinical cure rates were similar between groups (98.4% vs. 98.3%), but the combination group had a significantly higher global cure rate (96.6% vs. 85.3%, p = 0.044) and lower recurrence rate (1.7% vs. 13.1%, p = 0.032). No significant differences were found in diarrheal outcomes, functional ability, or adverse events. No patients discontinued treatment due to intolerance. In conclusion, adding S. boulardii to vancomycin reduced CDI recurrence without affecting functional recovery or increasing adverse events. © 2025. The Author(s). DOI: 10.1038/s41598-025-04986-2 PMCID: PMC12130261 PMID: 40457042 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests. Abbreviations: CDI, Clostridium difficile infection; PPI, proton pump inhibitor. Ethical approval: The study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. It was approved by the Research Ethics Committee of the Faculty of Medicine, Chiang Mai University (Study Code: MED-2564-08655). Consent to participate: Patients received written and oral information on the study and consented to participate and have their medical data used for research purposes.
9. BMC Gastroenterol. 2025 Apr 18;25(1):273. doi: 10.1186/s12876-025-03879-y. Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication. Jiang YZ(1), Ma K(1), Cui C(1), Li ZY(1), Wang XY(2). Author information: (1)Department of Gastroenterology, Changzhou Medical Center, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 68 Gehu middle road, Wujing District, Changzhou, Jiangsu Province, 213000, China. (2)Department of Gastroenterology, Changzhou Medical Center, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 68 Gehu middle road, Wujing District, Changzhou, Jiangsu Province, 213000, China. wxy20009@126.com. BACKGROUND: Helicobacter pylori (H. pylori) infection is a common chronic infection, and there are over half of the global population infected with H. pylori. It is still controversial whether the supplementation of Saccharomyces boulardii (S. boulardii) to bismuth quadruple therapy is beneficial for H. pylori eradication. AIM: To determine the effects of S. boulardii supplementation to bismuth quadruple therapy on H. pylori eradication. METHODS: We performed a systematic literature search across PubMed, Embase, Web of Science, and China National Knowledge Infrastructure for articles published up to October 2023. We calculated the pooled relative risk (RR) with the 95% confidence interval (CI). Statistical analyses were conducted using Stata/SE 15.1 software. RESULTS: Ten randomized controlled trials were included. Notably, S. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62). Specifically, it reduced the incidence of some gastrointestinal adverse effects and nonspecific adverse effects, including diarrhea (RR = 0.28, 95% CI: 0.22-0.36), constipation (RR = 0.32, 95% CI: 0.18-0.55), abdominal distention (RR = 0.39, 95% CI: 0.26-0.59), nausea (RR = 0.59, 95% CI: 0.36-0.97), and rash (RR = 0.49, 95% CI: 0.28-0.86). In the subgroup analysis, long-term eradication duration (> 10 days; RR = 1.08, 95% CI: 1.04-1.13) and S. boulardii supplementation to be started and stopped at the same time as eradication treatment (RR = 1.09, 95% CI: 1.04-1.14) were found to significantly improve the eradication rate regardless of the S. boulardii dose (500 mg/day, RR = 1.10, 95% CI: 1.03-1.17; 1000 mg/day, RR = 1.08, 95% CI: 1.03-1.12). CONCLUSIONS: The addition of S. boulardii to bismuth quadruple therapy significantly increased H. pylori eradication rates and decreased the adverse effects. We recommend adding 500 mg/day S. boulardii concurrently with bismuth quadruple therapy and continuing this therapy for > 10 days for optimal H. pylori eradication efficacy. © 2025. The Author(s). DOI: 10.1186/s12876-025-03879-y PMCID: PMC12008914 PMID: 40251486 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate: Not Applicable. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests. PRISMA 2009 checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
10. Drug Res (Stuttg). 2025 Jun;75(5):162-168. doi: 10.1055/a-2564-2569. Epub 2025 Apr 14. A Randomized, Controlled Study Evaluating Effects of Saccharomyces boulardii in Adult Patients with Asthma. Dezfouli KA(1)(2), Darban M(3), Hemmati M(4), Zahir M(5), Kermanshahi MS(6), Abdolshahi A(7), Sadr H(3), Bagheri B(4)(8). Author information: (1)Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran. (2)Department of Internal Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. (3)Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, Iran. (4)Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran. (5)Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (6)Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran. (7)Food Safety Research Center (salt), Semnan University of Medical Sciences, Semnan, Iran. (8)Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland. To determine the potential benefit of adding Saccharomyces boulardii (S. boulardii) probiotic supplementation to conventional treatments in asthmatic patients.In this randomized, double-blinded, and placebo-controlled trial 50 asthmatic patients were enrolled. The eligible subjects received either S. boulardii (N=25) or placebo (N=25) added to conventional treatments for three months. Spirometry parameters (FEV1, FVC, FEV1/FVC, and FEF 25-75%) and blood test parameters (CBC, eosinophil percentage, IgE, IL-5, ESR and CRP) were measured and compared at baseline and after treatment completion.The mean age was 39.22±12.55 years. As compared to baseline values, a significant improvement was noted in FEV1 in patients who received S. boulardii (p=0.026). Although the changes in FEV1, FVC, FEV1/FVC, and FEF 25-75% were comparable between the study groups, the differences were not statistically significant (p ˃ 0.05). In addition, patients who received probiotic showed lower levels of IL-5 and IgE in comparison with patients who received placebo.Our findings showed that the addition of S. boulardii to conventional treatments partially improved the pulmonary function and was associated with reductions in IgE and IL-5 levels. Thieme. All rights reserved. DOI: 10.1055/a-2564-2569 PMID: 40228543 [Indexed for MEDLINE] Conflict of interest statement: The authors have no conflicts of interest to declare.
11. Braz J Med Biol Res. 2025 Mar 24;58:e14196. doi: 10.1590/1414-431X2025e14196. eCollection 2025. Saccharomyces boulardii supplementation does not affect anaerobic power gain induced by short-term sprint interval training in physically active individuals. Hudson ASR(1)(2), Lisboa AMT(1), Andrade PVR(1), Bruzzi RS(1), Martins YAT(1), Soares DD(1), Martins FS(3), Wanner SP(1)(2). Author information: (1)Laboratório de Fisiologia do Exercício, Escola de Educação Física, Fisioterapia e Terapia Ocupacional, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. (2)Departamento de Ciências e Linguagens, Instituto Federal de Minas Gerais, Campus Bambuí, Bambuí, MG, Brasil. (3)Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. Sprint interval training (SIT), which consists of vigorous-intensity exercise interspersed with periods of rest or low-intensity exercise, can improve human anaerobic performance. Probiotic strains, including yeasts (e.g. Saccharomyces boulardii; Sb), have beneficial effects on human health; however, evidence regarding the effects of probiotics on anaerobic performance is unavailable. The current study investigated whether Sb supplementation influences the SIT-induced changes to the following performance variables: peak (PPO) and mean (MPO) power output. Fifteen healthy individuals (twelve men and three women) were randomly divided into two groups: placebo (PLA; n=8) and Sb (n=7). The individuals performed six SIT sessions on a cycle ergometer (four to seven 30-s all-out sprints thrice weekly). During the training period, participants ingested a capsule containing PLA or at least 1×109 Sb cells daily for 14 days. Performance-related variables were compared between the first and last training sessions. Sb supplementation did not influence the changes in PPO and MPO across the two weeks of training (P>0.05); therefore, the data from both groups were analyzed collectively to assess performance changes induced by SIT. Training increased PPO, an index of anaerobic power, in the sixth session compared to the first session (by 8±11% in the first sprint; +1.0±1.2 W/kg; P=0.008) but did not change MPO. In conclusion, short-term SIT improved the participants' anaerobic performance (power), as evidenced by increased PPO. Sb supplementation did not affect the improved anaerobic power caused by SIT. DOI: 10.1590/1414-431X2025e14196 PMID: 40136227 [Indexed for MEDLINE]
12. BMC Gastroenterol. 2024 Nov 26;24(1):430. doi: 10.1186/s12876-024-03524-0. Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori. Yu J(#)(1)(2), Cui C(#)(1), Ma K(1), Yang P(1)(2), Jiang Y(1), Wang X(3). Author information: (1)Department of Gastroenterology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 29 Xinglong Lane, Tianning District, Changzhou, Jiangsu Province, 213000, China. (2)Graduate School, Dalian Medical University, 9 West Section of Lushun South Road, Lvshunkou District, Dalian, Liaoning Province, 116000, China. (3)Department of Gastroenterology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 29 Xinglong Lane, Tianning District, Changzhou, Jiangsu Province, 213000, China. wxy20009@126.com. (#)Contributed equally BACKGROUND: Currently, Vonoprazan (VPZ) and amoxicillin dual regimen (VA-dual) has not achieved satisfied efficacy as the first-line treatment for Helicobacter pylori (H. pylori) infection in China. Thus, we aimed to determine the effect of VA-dual plus Saccharomyces boulardii (S. boulardii) on H. pylori eradication rate. METHODS: Naive H. pylori-infected patients were randomly allocated to the ECAB group [20-mg esomeprazole, 500-mg clarithromycin, 1000-mg amoxicillin, and 220-mg bismuth twice/day for 14 days] or the VAS group [20-mg VPZ twice/day, 750-mg amoxicillin three times/day, and 250-mg S. boulardii twice/day for 10 days]. Factors associated with eradication success were explored, and cost-effectiveness analyses were also performed. RESULTS: Herein, 126 patients were finally included and randomly assigned to the two groups in a 1:1 ratio. The H. pylori eradication rates of VAS and ECAB groups by intention-to-treat analysis were 87.3% and 88.9% (P = 1.000) and by per-protocol analysis were 87.3% and 91.8% (P = 0.560), respectively. The ECAB group had a significantly higher incidence of adverse events than the VAS group. Superior H. pylori eradication in the VAS group was related to small body surface area and being a non-smoker. The cost-effectiveness ratio of the VAS group was less than that of the ECAB group. CONCLUSIONS: Addition of S. boulardii to VA-dual for 10 days is as effective as the 14-days bismuth-based quadruple regimen while ensuring fewer adverse events and lesser cost. This regimen is particularly suitable for low-BSA patients or non-smokers. TRIAL REGISTRATION: Chinese Clinical trial Registry No. ChiCTR2100055101 31/12/2021. © 2024. The Author(s). DOI: 10.1186/s12876-024-03524-0 PMCID: PMC11590635 PMID: 39592940 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate: The study was reviewed and approved by the Clinical Medical Technical Ethics Committee of the Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University (No. [2021] YLJSC016).This study is registered at Chinese Clinical trial Registry. The registration identification number is ChiCTR2100055101.All study participants provided informed written consent prior to study enrollment. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
13. Zhongguo Dang Dai Er Ke Za Zhi. 2024 Oct 15;26(10):1108-1114. doi: 10.7499/j.issn.1008-8830.2401129. [A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. [Article in Chinese; Abstract available in Chinese from the publisher] Zhang SW(1), Zhi X(1), Wang MY(1), Shen DL(1). Author information: (1)Department of Pediatric Gastroenterology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. OBJECTIVES: To evaluate the preventive effects of Saccharomyces boulardii powder and tetragenous viable Bifidobacterium tablets on antibiotic-associated diarrhea (AAD) in infants and young children. METHODS: Children under three years old admitted to the Department of Pediatrics, Affiliated Hospital of Xuzhou Medical University due to non-gastrointestinal infections and requiring antibiotic treatment from July to December 2023 were enrolled. The children were randomly divided into a control group (n=47), a Saccharomyces boulardii group (n=70), and a Bifidobacterium group (n=65) using a random number table method. The control group received antibiotics and symptomatic supportive treatment according to relevant clinical guidelines. In addition to the treatment given to the control group, the Saccharomyces boulardii group and the Bifidobacterium group were respectively administered with Saccharomyces boulardii powder and tetragenous viable Bifidobacterium tablets. Based on the duration of probiotic use (7 days, 14 days, and 21 days), the Saccharomyces boulardii group was further divided into 7 d, 14 d, and 21 d subgroups, and similarly for the Bifidobacterium group. The incidence of AAD and ratio of cocci to bacilli in feces were compared among the groups after treatment. RESULTS: The incidence rate of AAD in both the Saccharomyces boulardii group and the Bifidobacterium group was lower than that in the control group (P<0.017). The duration of AAD and the length of hospital stay were shorter in the Saccharomyces boulardii and Bifidobacterium groups compared to the control group (P<0.05). In the control group, the ratio of cocci to bacilli in feces on days 7, 14, and 21 was higher than on day 1 (P<0.05). Within-group comparisons showed that the ratio of cocci to bacilli in feces on day 14 in the Bifidobacterium 14 d and 21 d groups were lower than on day 1 (P<0.05); and the ratios on day 14 in the control group, Saccharomyces boulardii 14 d group, Saccharomyces boulardii 21 d group, Bifidobacterium 14 d group, and Bifidobacterium 21 d group were lower than on day 7 (P<0.05). The ratios on day 21 in the control group and the Saccharomyces boulardii 21 d group were lower than on days 7 and 14 (P<0.05). Between-group comparisons indicated that on day 7, the ratios of cocci to bacilli in feces in the Saccharomyces boulardii 7 d, 14 d, 21 d groups, and Bifidobacterium 7 d, 14 d, 21 d groups were all lower than in the control group (P<0.05); on day 14, the ratios of cocci to bacilli in feces 14 d and 21 d groups were lower than in the control group and the Bifidobacterium 7 d group (P<0.05). CONCLUSIONS: Both Saccharomyces boulardii and tetragenous viable Bifidobacterium can effectively improve gut microbiota and prevent the occurrence of AAD in infants and young children. Compared to short-term treatment, appropriately extending the duration of probiotic therapy can further improve the structure of gut microbiota. Publisher: 目的: 评价布拉氏酵母菌散及双歧杆菌四联活菌片对婴幼儿抗生素相关性腹泻（antibiotic-associated diarrhea, AAD）的预防作用。方法: 选取2023年7—12月因非胃肠道感染入住徐州医科大学附属医院儿科并需抗生素治疗的3岁以下患儿作为研究对象，采用随机数字表法随机分为对照组（n=47）、布拉氏酵母菌组（n=70）、双歧杆菌组（n=65）。对照组根据相关诊疗规范应用抗生素及对症支持治疗。除对照组采用的治疗外，布拉氏酵母菌组和双歧杆菌组分别加用布拉氏酵母菌散和双歧杆菌四联活菌片治疗，并根据益生菌使用时间将布拉氏酵母菌组分为布拉氏酵母菌7 d、14 d、21 d组和双歧杆菌7 d、14 d、21 d组。比较各组患儿应用抗生素后AAD发生率和粪便球菌与杆菌比例。结果: 布拉氏酵母菌组和双歧杆菌组的AAD发生率均低于对照组（P<0.017）。布拉氏酵母菌组和双歧杆菌组AAD持续时间和住院时间均短于对照组（P<0.05）。对照组在第7天、14天、21天的粪便球菌与杆菌比例均高于第1天（P<0.05）。组内比较显示，双歧杆菌14 d组、21 d组在治疗第14天的粪便球菌与杆菌比例低于第1天（P<0.05）；对照组、布拉酵母菌14 d组、布拉酵母菌21 d组、双歧杆菌14 d组、双歧杆菌21 d组在治疗第14天的粪便球菌与杆菌比例低于第7天（P<0.05）；对照组、布拉氏酵母菌21 d组在治疗第21天时粪便球菌与杆菌比例低于第7天及第14天（P<0.05）。组别间比较显示，第7天时，布拉氏酵母菌7 d、14 d、21 d组以及双歧杆菌7 d、14 d、21 d组粪便球菌与杆菌比例均低于对照组（P<0.05）；第14天时，双歧杆菌14 d组和21 d组粪便球菌与杆菌比例均低于对照组和双歧杆菌7 d组（P<0.05）。结论: 布拉氏酵母菌和双歧杆菌四联活菌均能有效改善肠道菌群，预防婴幼儿AAD的发生；与短期治疗相比，适当延长益生菌疗程可进一步改善肠道菌群结构。. DOI: 10.7499/j.issn.1008-8830.2401129 PMCID: PMC11527406 PMID: 39467682 [Indexed for MEDLINE] Conflict of interest statement: 所有作者声明无利益冲突。
14. Food Funct. 2024 Jul 15;15(14):7658-7668. doi: 10.1039/d4fo01269k. Beneficial effects of a new probiotic formulation on adipocytokines, appetite-regulating hormones, and metabolic parameters in obese women. Okuka N(1), Milinkovic N(2), Velickovic K(3), Polovina S(4)(5), Sumarac-Dumanovic M(4)(6), Minic R(7), Korčok D(5), Djordjevic B(8), Ivanovic ND(8). Author information: (1)University of Banja Luka, Faculty of Medicine, Department of Bromatology, 78000 Banja Luka, Bosnia and Herzegovina. nina.vukicevic@med.unibl.org. (2)University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry, 11000, Belgrade, Serbia. (3)University of Belgrade, Faculty of Biology, Department of Cell and Tissue Biology, 11000 Belgrade, Serbia. (4)Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center of Serbia, 11000 Belgrade, Serbia. (5)Faculty of Pharmacy, Novi Sad, University Business Academy, 21000 Novi Sad, Serbia. (6)School of Medicine, University of Belgrade, Clinic for Endocrinology, Diabetes and Diseases of Metabolism, 11000 Belgrade, Serbia. (7)Institute of Virology, Vaccines and Sera "Torlak", Department of Protein Engineering and Biochemistry, 11000 Belgrade, Serbia. (8)University of Belgrade, Faculty of Pharmacy, Department of Bromatology, 11000 Belgrade, Serbia. Obesity is often accompanied by low-grade chronic inflammation and metabolic syndrome. It has been established that microbiota influences many physiological processes, including the development of obesity, and dysbiosis has been observed in obese individuals. In this study, we aimed to evaluate the impact of a new probiotic formulation, containing two probiotic strains and the bioactive compound octacosanol, on body weight, metabolic parameters, and concentrations of certain adipocytokines and appetite-regulating hormones in obese women. This double blind placebo-controlled supplementary intervention study included twenty-five women in the intervention group and twenty-three in the placebo group, and it lasted 12 weeks. Daily oral supplementation included 7 × 1010 CFU of Lactiplantibacillus plantarum 299v (DSM9843), 5 × 109 CFU of Saccharomyces cerevisiae var. boulardii (DBVPG6763), and 40 mg of octacosanol or placebo. Body weight, metabolic parameters, adipocytokines, and appetite-regulating hormones were assessed before (T0) and after the intervention (T1). After the intervention, significantly lower median concentrations of CRP (p = 0.005) and IL-6 (p = 0.012) were measured in the intervention group than the baseline, while the median concentrations of ghrelin (p = 0.026) and HDL-cholesterol (p = 0.03) were significantly increased. The intervention group had lower CRP levels (p = 0.023) and higher ghrelin levels (p = 0.006) than the placebo group. Significant changes in BMI between groups were not observed. In summary, although the new probiotic formulation showed beneficial effects on IL-6, CRP, HDL, and ghrelin levels, its potential effects on regulating triglyceride, insulin, and glucose levels require further studies before the novel dietary intervention could be considered a useful adjuvant therapy and an effective strategy for the management of obesity and obesity-associated comorbidities. DOI: 10.1039/d4fo01269k PMID: 38953736 [Indexed for MEDLINE]
15. Sci Rep. 2024 Jun 7;14(1):13152. doi: 10.1038/s41598-024-63894-z. Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection. Zhang Y(#)(1), Lu B(#)(2), Dong Y(1), Zhang Y(1), Du Q(1), Chen Y(3)(4), Zhang Z(5). Author information: (1)Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, People's Republic of China. (2)Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, People's Republic of China. (3)Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, People's Republic of China. yechen_fimmu@163.com. (4)Integrative Microecology Clinical Center, Shenzhen Key Laboratory of Gastrointestinal Microbiota and Disease, Shenzhen Clinical Research Center for Digestive Disease, Shenzhen Technology Research Center of Gut Microbiota Transplantation, Shenzhen Hospital, Southern Medical University, 1333 Xinhu Road, Bao'an District, Shenzhen, 518101, People's Republic of China. yechen_fimmu@163.com. (5)Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, People's Republic of China. zzy6565@sina.com. (#)Contributed equally To assess the effectiveness and safety of combining Saccharomyces boulardii powder with triple therapy as a primary approach for eradicating H. pylori infection, a total of 144 patients who tested positive for H. pylori and diagnosed with non-ulcer dyspepsia underwent endoscopy at two national centers between June 2017 and March 2019 were included. The patients were categorized into three groups using a subsection randomization method and received initial H. pylori eradication treatments. Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment. According to PP analysis showed the eradication rates for the SRAC group was 75%, BRAC was 93.18% and RAC was 65.2%. Group BRAC exhibited a marginally higher eradication rate compared to other groups. However, patients receiving Saccharomyces boulardii treatment exhibited an overall reduction in initial dyspepsia symptoms by the end of the treatment period. When employed as a primary strategy, the combination of Saccharomyces boulardii powder with triple therapy displayed notable efficacy and smaller gastrointestinal side effects in eradicating initial H. pylori infections among non-ulcer dyspepsia patients. Moreover, this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety. © 2024. The Author(s). DOI: 10.1038/s41598-024-63894-z PMCID: PMC11161611 PMID: 38849408 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no competing interests.
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.